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(IC95% [1.14–10.94]; P = 0.03) more chances to have Nd:Yag
laser than ReSTOR® eyes, after adjusting for age at surgery.
CONCLUSIONS:This analysis conducted at one year suggested
that following usual surgical practice in a private setting,
ReSTOR® eyes had signiﬁcantly less capsulotomy than those
implanted with Acrilisa®. Avoiding Nd:Yag laser and its potential
complications is important, especially in a young population.
Analyses at two and three years will be required to conﬁrm these
ﬁndings
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OBJECTIVES: To identify and characterize glaucoma patient
compliance proﬁles and to evaluate the impact on treatment
efﬁcacy. METHODS: A computerized device (Travalert®) that
collects daily instillation time and number of drops was given to
a cohort of patients for three months. A patient was declared
compliant when at least 2 drops per day were instilled, one in
each eye. Two compliance rates were calculated per week: during
the weekend and the remaining ‘working’ days. Principal com-
ponent analysis (PCA) was performed followed by an ascendant
hierarchical classiﬁcation (AHC) to identify groups of compliant
patients. Their characteristics were compared using chi-square or
ANOVA. RESULTS: A total of 113 patients were included (mean
age 66.5, 51.8% male), and 86.7% had primary open angle
glaucoma. Mean IOP was 24.2 mmHg before using Travalert®.
57.5% were treated with DuoTrav® and 42.5% with Travatan®.
PCA identiﬁed two axes (compliance intensity and week effect),
explaining 63.0% of the variance. AHC identiﬁed 3 compliance
groups: good (56.6% of the patients, compliance around 80%),
mild (21.2% of the patients, compliance around 50%) and poor
(22.1% of the patients, compliance around 20%). No predictive
variables (demographic or medical) of poor compliance were
identiﬁed. At the last visit, IOP was 16.1 mmHg on average and
statistically signiﬁcantly higher in the poor compliance group
(17.7 mmHg; P = 0.02). CONCLUSIONS: Compliance, mea-
sured objectively with a medical device, remains a major issue in
glaucoma treatment since about half the patients had compliance
lower than 80%. This impacted IOP control, a surrogate end-
point of glaucoma progression. None of the medical and demo-
graphics variables were associated with poor compliance
suggesting that forthcoming compliance research should identify
new targets (e.g. behavior) to identify patients beneﬁting from a
compliance training program.
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OBJECTIVES: To estimate the effectiveness of moxiﬂoxacin in
the treatment of bacterial conjunctivitis in adults using data
from the available randomized clinical trials METHODS: Four
randomized clinical trials were identiﬁed. Three compared
moxiﬂoxacin against placebo and one against oﬂoxacin. Effec-
tiveness parameters included early (day 3 to 5) and late (day 7
to 10) clinical efﬁcacy, late bacteriological efﬁcacy, and drop-out
due to lack of efﬁcacy. Fixed (Mantel-Haenzel) and random
(Der Simonian and Laird) effects models for risk ratios and risk
differences associated with treatment effects were estimated and
tests of homogeneity of effects across studies were done. All
analyses were conducted on the intention to treat population.
RESULTS: A total of 609 moxiﬂoxacin-treated patients and 606
placebo-treated patients were included in the meta-analysis.
Drop-out rates due to lack of efﬁcacy were consistently higher
for patients receiving placebo. However, there was signiﬁcant
heterogeneity in the estimates of drop-out rates for moxiﬂoxa-
cin and placebo groups across studies (p = 0.04). The probabil-
ity of both an early and a late clinical remission was higher with
moxiﬂoxacin (RR, 1.17, P = 0.001; RR, 1.13; P = 0.05, respec-
tively). The late bacteriological remission rate was about 25%
higher (RR, 1.26, P = 0.001) for patients treated with moxi-
ﬂoxacin. Eleven patients had to be treated with moxiﬂoxacin to
gain one additionanl clinical remission and 6 to gain one more
bacteriological remission. In comparison to oﬂoxacin, the prob-
ability of drop-out due to lack of efﬁcacy for the bacteriologi-
cally documented population was 2.63-fold lower (P = 0.03)
with moxiﬂoxacin; one extra failure could be avoided for every
19 patients treated. CONCLUSIONS: This meta-analysis sug-
gests higher clinical and bacteriological efﬁcacy of Moxiﬂoxacin
compared with placebo. The estimates reported here should be
interpreted with caution, given the small number of clinical
trials with published results. The lower proportion of drop-outs
for patients treated with moxiﬂoxacin compared with oﬂoxacin
suggests a lower use of rescue treatments for patients receiving
moxiﬂoxacin.
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OBJECTIVES: To compare the efﬁcacy of topical ocular
hypotensives for the treatment of intraocular hypertension and
glaucoma. Adverse events that may affect patients’ willingness to
comply with treatment were also assessed. METHODS: A sys-
tematic review was conducted to identify randomized controlled
trials in patients with glaucoma or ocular hypertension with a
prostaglandin analogue treatment arm. A total of 181 eligible
articles were identiﬁed with 73 suitable for meta-analysis. A
mixed treatment comparison (MTC) was performed to estimate
the relative efﬁcacy of the treatments. Studies connected to
latanoprost and reporting the mean and standard deviation in
absolute intraocular pressure (IOP) at three months were used in
the MTC since this maximised the analysis dataset. Baseline IOP
was included as a covariate in the MTC. Random effects models
were used, as study variance indicated some degree of heteroge-
neity. A second MTC was conducted to estimate the rate of
hyperaemia-type adverse events. RESULTS: The mean IOP at
three months for latanoprost is 17.42 mmHg from a baseline of
23.5 mmHg. Latanoprost is statistically signiﬁcantly better at
lowering IOP versus timolol, and latanoprost and timolol is
statistically signiﬁcantly more efﬁcacious versus latanoprost
alone. There were no further statistically signiﬁcant differences in
mean IOP for latanoprost versus any other treatments. The
hyperaemia event rate for latanoprost is 25.18%. Using the odds
ratio results compared to latanoprost, timolol has a statistically
signiﬁcantly lower event rate. Travoprost, bimatoprost, tra-
voprost and timolol, bimatoprost and timolol, latanoprost and
brimonidine, latanoprost and dorzolamide have statistically sig-
niﬁcantly higher event rates. CONCLUSIONS: The results indi-
cate that there is no clinically relevant difference in IOP lowering
between treatments except for timolol. However there are
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